Loading
Immunotherapy and Immune Responses / CAR-T Cell Therapy Research · Journal article
Expert Opinion on Biological Therapy · August 17, 2026
A consensus or society position rather than new primary data.
This is a narrative expert review synthesizing a decade of immune checkpoint inhibitor expansion across oncology from 2011 to 2025. It documents established clinical indications (melanoma, head and neck, kidney, liver, urothelial cancers, and microsatellite instability-high tumors) where PD-1/PD-L1 testing is no longer required, and identifies gaps in benefit in other cancer subsets with recommendations for future combination strategies.
Narrative literature review with expert opinion. English-language publications reporting on immune checkpoint inhibitors across oncology.. Intervention: Immune checkpoint inhibitors targeting CTLA-4 and/or PD-1/PD-L1.
Since 2011, ICIs have expanded across virtually all fields of oncology with meaningful impact in multiple cancer types In melanoma, head and neck, kidney, liver, and urothelial cancers, PD-L1 testing outside clinical trials is no longer required Tumor-agnostic efficacy of PD-1 ± CTLA-4 inhibition in microsatellite instability-high cancers is well established
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize that PD-L1 testing is no longer routinely required outside trials for established indications (melanoma, head and neck, kidney, liver, urothelial cancers) and that microsatellite instability-high status predicts ICI response tumor-agonistically. For other cancers with limited ICI benefit, biomarker-driven strategies and combination approaches warrant investigation.
A narrative literature review synthesizing a decade of ICI expansion across oncology, offering expert opinion on established indications and future directions rather than reporting original trial results.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize that PD-L1 testing is no longer routinely required outside trials for established indications (melanoma, head and neck, kidney, liver, urothelial cancers) and that microsatellite instability-high status predicts ICI response tumor-agonistically. For other cancers with limited ICI benefit, biomarker-driven strategies and combination approaches warrant investigation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
INTRODUCTION: Immune checkpoint inhibitors (ICIs) have transformed oncology by targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1), thereby enabling responses across multiple malignancies. Despite these advances, benefits remain limited in many cancers. AREAS COVERED: A narrative literature review was conducted using PubMed, Embase, and the Cochrane Library to identify English-language publications from 1 January 2000, through 31 December 2025. Eligible sources included pivotal trials, real-world studies, reviews, and relevant clinical practice guidelines. EXPERT OPINION: Since 2011, ICIs have permeated virtually all fields of oncology, with meaningful impact across many cancer types. Beyond expanding indications, they offer potential for durable benefit in many responders. In melanoma, head and neck, kidney, liver, and urothelial cancers, PD-L1 testing outside clinical trials is no longer required. Tumor-agnostic efficacy of PD-1 ± CTLA-4 inhibition in microsatellite instability-high cancers is well established. Limited benefit in other cancer subsets highlights the need for biomarker discovery and optimization of therapeutic strategies, including addition of antibody-drug conjugates to ICIs, next-generation checkpoint modulation, personalized neoantigen vaccines, and engineered cellular immunotherapy. Effective future therapies should also address comprehensive profiling of tumor cells, their molecular expression patterns, and constantly changing dynamics of the tumor microenvironment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.